GSK3B and pancreatic neoplasm: In a preliminary study, we found that a small-molecule GSK3β inhibitor increased pancreatic cancer cell sensitivity to gemcitabine in cell culture and tumor xenografts when its dose and treatment protocol were optimized, and have identified the molecular mechanisms underlying the increased sensitivity [86].